You are viewing: Rest Of Europe AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The Rest Of Europe AI in Life Science Market was valued at $1017.6 Million in 2026 and projected to reach to $3234.6 Million by 2031, representing a compound annual growth rate of 26.0%. Rest Of Europe's AI in Life Science market is positioned for substantial growth through 2031, driven by increasing investments in healthcare technology infrastructure and regulatory support for digital innovation.

Rest Of Europe AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 26.0%, reflecting strong adoption of artificial intelligence technologies across pharmaceutical research, diagnostics, and clinical development in the region.
  • Rest Of Europe is capitalizing on regulatory harmonization, increased R&D investment, and growing collaboration between academic institutions and life science companies to accelerate AI integration. The market dynamics in Rest Of Europe are driven by rising healthcare costs, demand for faster drug discovery cycles, and government initiatives supporting digital health innovation.
  • Rest Of Europe's life science sector is increasingly leveraging machine learning for genomics analysis, predictive analytics, and personalized medicine applications.
  • Between 2026 and 2031, Rest Of Europe is expected to see significant investment in AI infrastructure, talent development, and cross-border partnerships that will further strengthen its competitive position in the global AI-enabled life science ecosystem..

Key Market Statistics

  • CAGR (2026-2031) 26.0% CAGR
  • Market Size, 2026 ~USD 1017.6 Million
  • Forecast, 2031 ~USD 3234.6 Million
  • Country Rest Of Europe

Rest Of Europe AI in Life Science Market Overview

Strong Regional Growth Trajectory :

Rest Of Europe's AI in Life Science market is expanding at 26% CAGR, growing from $1,017.6 million in 2026 to $3,234.6 million by 2031, demonstrating accelerating adoption across the region.

Pharmaceutical Research Innovation :

European pharmaceutical companies are increasingly leveraging AI for drug discovery and development, reducing time-to-market and improving R&D efficiency across Rest Of Europe markets.

Diagnostic Technology Advancement :

AI-powered diagnostic solutions are gaining traction in Rest Of Europe's healthcare systems, enabling faster disease detection and personalized treatment pathways in clinical settings.

Clinical Development Optimization :

Rest Of Europe's life science sector is adopting AI for clinical trial management, patient recruitment, and data analysis, streamlining development processes and reducing operational costs.

Rest Of Europe AI in Life Science Market Dynamics

  • The region's strong pharmaceutical and biotech ecosystem is embracing AI solutions to enhance research productivity and accelerate time-to-market for new therapeutics.
  • Healthcare providers across Rest Of Europe are integrating AI-powered diagnostics and clinical decision support systems to improve patient outcomes and operational efficiency. The market expansion is supported by growing collaboration between academic institutions, healthcare providers, and technology companies throughout Rest Of Europe.
  • Regulatory frameworks are evolving to accommodate AI applications in life sciences, while funding initiatives promote digital health innovation.
  • As healthcare systems prioritize precision medicine and personalized treatment approaches, AI adoption in Rest Of Europe will continue accelerating, creating significant opportunities for solution providers and life science organizations..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • Rest Of Europe's AI in Life Science market will grow from $1,017.6M (2026) to $3,234.6M (2031) at a 26.0% CAGR.
    • Rest Of Europe is leveraging AI for drug discovery, genomics, and personalized medicine to reduce development timelines.
    • Rest Of Europe benefits from regulatory harmonization and cross-border collaboration that accelerates AI adoption.
    • Rest Of Europe's investment in AI infrastructure and talent will strengthen its position in the global life science market.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    Rest Of Europe AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    Target Audience

    • Pharmaceutical & Biotech Companies : Rest Of Europe-based and international pharma firms need regional market intelligence to guide R&D investments, AI tool selection, and competitive positioning in drug discovery and development.
    • Healthcare Technology Providers : AI software and platform vendors targeting Rest Of Europe's life science sector require market data to identify customer segments, assess demand, and develop region-specific go-to-market strategies.
    • Healthcare System Administrators : Hospital networks and diagnostic centers in Rest Of Europe need insights on AI implementation trends, clinical outcomes, and ROI metrics to justify technology investments and improve patient care.
    • Investment & Private Equity Firms : Investors evaluating life science and healthcare technology opportunities in Rest Of Europe require detailed market forecasts and growth drivers to assess portfolio companies and identify acquisition targets.
    • Government & Policy Makers : Rest Of Europe's health ministries and regulatory bodies need market intelligence to inform digital health policies, funding priorities, and innovation frameworks supporting AI adoption in life sciences.

    Key Companies in the Rest Of Europe AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations specific to Rest Of Europe ($1,017.6M in 2026, $3,234.6M in 2031) with detailed growth projections to support strategic planning and investment decisions.
    • Competitive Landscape Analysis : Understand key players, market share distribution, and competitive positioning within Rest Of Europe's AI in Life Science sector to identify partnership and acquisition opportunities.
    • Segment-Specific Insights : Access detailed breakdowns of pharmaceutical research, diagnostics, and clinical development segments within Rest Of Europe to target high-growth opportunities aligned with your business focus.
    • Regulatory & Market Entry Strategy : Gain actionable intelligence on Rest Of Europe's regulatory environment, reimbursement policies, and market entry barriers to accelerate commercialization of AI life science solutions.
    • Investment & Growth Opportunities : Identify emerging trends, funding patterns, and growth drivers specific to Rest Of Europe to optimize resource allocation and capitalize on the region's 26% CAGR expansion.

    Frequently asked questions

    What is the market size of AI in Life Science in Rest Of Europe in 2026?

    Rest Of Europe's AI in Life Science market is valued at $1,017.6 million in 2026.

    What is the projected market size for Rest Of Europe by 2031?

    Rest Of Europe's AI in Life Science market is projected to reach $3,234.6 million by 2031.

    What is the CAGR for Rest Of Europe's AI in Life Science market?

    Rest Of Europe's AI in Life Science market is expected to grow at a compound annual growth rate of 26.0% from 2026 to 2031.

    What are the primary applications of AI in Rest Of Europe's life science sector?

    Rest Of Europe is utilizing AI for drug discovery acceleration, genomics analysis, predictive analytics, clinical trial optimization, and personalized medicine development.

    What factors are driving AI adoption in Rest Of Europe's life science market?

    Rest Of Europe's AI adoption is driven by rising healthcare costs, demand for faster drug development, regulatory harmonization, government digital health initiatives, and increased R&D investment.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status